Understanding how Ewing sarcoma affects gene transcription
Official title: Phase separation control of transcription in Ewing sarcoma
Funded at University of Arizona · NIH-10983780 · Data updated 2026-11-12
This study is looking at how a specific protein linked to Ewing sarcoma affects how genes work in cells, with the hope of finding new ways to treat this type of bone cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | December 16, 2021 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $305,499 |
| NIH project number | 5R01CA259570-04 |
| Project ID | NIH-10983780 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents diagnosed with Ewing sarcoma or those at risk due to genetic factors.
✕Less likely to help
Patients with Ewing sarcoma who do not have the EWS-FLI1 fusion protein may not benefit from this research.
What this research studies
This research investigates the mechanisms by which the EWS-FLI1 fusion protein, commonly found in Ewing sarcoma, alters gene transcription. It focuses on how this protein interacts with other proteins to form granules that disrupt normal cellular processes, potentially leading to tumor development. By isolating these granules and studying their composition and function, the research aims to provide insights into the transcriptional regulation in Ewing sarcoma. This could help identify new therapeutic targets for this aggressive bone cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for Ewing sarcoma, improving outcomes for affected patients.
How similar studies have gone: Previous research has shown promise in understanding the role of protein interactions in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Schwartz, Jacob C. — University of Arizona
- Study coordinator: Schwartz, Jacob C.
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.